Metropolis Healthcare has announced its audited consolidated financial results for the fourth quarter & financial year 2022.
FY22 financial highlights
Rs 1,228 crore: Revenue +23 per cent YoY
Rs 362 crore: EBITDA (Before CSR, ESOP & One-time acquisition cost) +20 per cent YoY
29.4 per cent: EBITDA Margin (Before CSR, ESOP & Onetime acquisition cost)
Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “I am extremely pleased to share that inspite of all the challenges faced on account of covid led supply chain disruptions, we were able to record our highest ever Revenue, EBITDA & PAT in FY22. Strong performance was on the back of robust growth in the sustainable non-covid business. During the year, we have made significant investments in digital, marketing, widening of leadership team and expansion of service network. These investments we make now will enable us to create a backbone for the next level of growth that we envisage in the business and help us safeguard our margins keeping in view the increased competitive intensity in coming times. Going ahead, we will continue to build the brand on scientific basis, invest in core focus areas and on the acquisition front, drive the synergies at Hitech through quick & smooth integration.”
- Advertisement -